KR102500124B1 - Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate - Google Patents

Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate Download PDF

Info

Publication number
KR102500124B1
KR102500124B1 KR1020227030825A KR20227030825A KR102500124B1 KR 102500124 B1 KR102500124 B1 KR 102500124B1 KR 1020227030825 A KR1020227030825 A KR 1020227030825A KR 20227030825 A KR20227030825 A KR 20227030825A KR 102500124 B1 KR102500124 B1 KR 102500124B1
Authority
KR
South Korea
Prior art keywords
group
added
fluorophenyl
pyrrole
mmol
Prior art date
Application number
KR1020227030825A
Other languages
Korean (ko)
Other versions
KR20220127369A (en
Inventor
이사오 오오이
마코토 이와타
Original Assignee
닛뽕 케미파 가부시키가이샤
재팬 소파루심 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 닛뽕 케미파 가부시키가이샤, 재팬 소파루심 가부시키가이샤 filed Critical 닛뽕 케미파 가부시키가이샤
Publication of KR20220127369A publication Critical patent/KR20220127369A/en
Application granted granted Critical
Publication of KR102500124B1 publication Critical patent/KR102500124B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333Radicals substituted by oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B51/00Introduction of protecting groups or activating groups, not provided for in the preceding groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B61/00Other general methods
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Catalysts (AREA)

Abstract

포르밀화, 탈보호 반응에 의한 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조 방법 및 술포닐화 등에 의한 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민모노푸마르산염의 제조에 관한 것이다.Method for producing 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde by formylation and deprotection reaction and 1-[5-(2-fluorophenyl)-1-(by sulfonylation, etc. It relates to the production of pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate.

Description

1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민모노푸마르산염의 제조법 {PRODUCTION METHOD FOR 1-[5-(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL]-N-METHYLMETHANAMINE MONOFUMARATE}Method for producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate {PRODUCTION METHOD FOR 1-[5 -(2-FLUOROPHENYL)-1-(PYRIDIN-3-YLSULFONYL)-1H-PYRROL-3-YL]-N-METHYLMETHANAMINE MONOFUMARATE}

본 발명은, 산 분비 억제약인 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민모노푸마르산염 및 그 중간체의 제조 방법에 관한 것이다.The present invention relates to 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate, which is an acid secretion inhibitor, and It relates to a method for preparing the intermediate.

하기 식으로 나타내는 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민모노푸마르산염 (이하, 보노프라잔푸마르산염) 은, 칼륨 이온 경합형 애시드 블로커이고, 칼륨 이온의 H+, K±ATPase 에 대한 결합을 저해하고, 위산 분비를 억제하므로, 위·십이지장 궤양 등의 치료나 예방, 헬리코박터·파일로리 제균시의 위 내 pH 조정에 사용되고 있다. 보노프라잔푸마르산염은 기존의 프로톤 펌프 인히비터와 비교하여, 산에 대해 안정적이고, 유효 농도에 대한 도달이 빠르고, 복용으로부터 작용 발현까지가 빨라 위산을 장시간에 걸쳐서 강하게 억제하는 것이 알려져 있다.1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate represented by the following formula (hereinafter referred to as bonofra Zanfumarate) is a potassium ion-competitive acid blocker, inhibits the binding of potassium ions to H+, K±ATPase, and inhibits gastric acid secretion, so it is used for treatment or prevention of gastric and duodenal ulcers, and eradication of Helicobacter pylori. It is used to adjust pH in the stomach. Compared to conventional proton pump inhibitors, vonoprazan fumarate is known to be stable against acid, reach an effective concentration quickly, and show action from ingestion to onset quickly, strongly inhibiting gastric acid over a long period of time.

[화학식 1][Formula 1]

Figure 112022093424482-pat00001
Figure 112022093424482-pat00001

보노프라잔푸마르산염의 제조 방법에 대해서는, 예를 들어 특허문헌 1 에는, 합성 중간체인 피롤-3-카르복시알데히드 유도체에 대해, 하기 식으로 나타내는 시아노 화합물로부터 피롤체를 거쳐 합성하는 방법이 개시되어 있다.Regarding the production method of vonoprazan fumarate, for example, Patent Document 1 discloses a method of synthesizing a pyrrole-3-carboxyaldehyde derivative, which is a synthetic intermediate, from a cyano compound represented by the following formula via a pyrrole form. .

[화학식 2][Formula 2]

Figure 112022093424482-pat00002
Figure 112022093424482-pat00002

이 방법에서는 [2-(2-플루오로페닐)-2-옥소에틸]프로판디니트릴 (a) 를 원료로 하고 있다. 이 원료는, 특허문헌 2 에 기재된 방법에 의해 제조할 수 있는 것이 기재되어 있고, 브롬화 2-플루오로페나실로부터 말로노니트릴의 반응에 의해 합성하는 것이 개시되어 있다. 또, 브롬화 2-플루오로페나실은, 일반 공지된 방법에 의해 제조할 수 있는 것이 기재되어 있다. 구체적인 기재는 없지만, 예를 들어 아세트산 중에서 브롬과 반응시키는 방법 (비특허문헌 1) 이나, 염화알루미늄의 존재하, 브롬과 반응시키는 방법 등이 알려져 있다 (비특허문헌 2). 원료의 합성에 2 공정을 필요로 하기 때문에, 목적 화합물의 제조에 많은 공정이 필요하게 된다. 또 이들 반응에서는, 독성이나 환경에 대한 영향이 우려되는 말로노니트릴이나 부식성, 자극성이 강한 브롬을 필요로 하므로, 보다 인체 및 환경에 대한 안전을 배려한 제조 방법이 요구된다. 또, 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드는, 원료로부터 수율 53 % ∼ 60 % 로 합성되고 있고, 수율의 개선도 요구된다.In this method, [2-(2-fluorophenyl)-2-oxoethyl]propanedinitrile (a) is used as a raw material. It is described that this raw material can be produced by the method described in Patent Document 2, and it is disclosed that it is synthesized by reaction of malononitrile from 2-fluorophenacyl bromide. In addition, it is described that 2-fluorophenacyl bromide can be produced by a generally known method. Although there is no specific description, for example, a method of reacting with bromine in acetic acid (Non-Patent Document 1), a method of reacting with bromine in the presence of aluminum chloride, and the like are known (Non-Patent Document 2). Since two steps are required for the synthesis of raw materials, many steps are required for the production of the target compound. In addition, since these reactions require malononitrile, which is concerned about toxicity and environmental impact, and bromine, which is highly corrosive and irritating, a manufacturing method that takes more safety into consideration for the human body and the environment is required. In addition, 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde is synthesized from raw materials in a yield of 53% to 60%, and improvement in yield is also required.

따라서, 인체나 환경에 대한 영향이 적고, 보다 짧은 공정이고 수율이 좋은 제조 방법이 요구된다.Therefore, there is a need for a manufacturing method with less impact on the human body or the environment, a shorter process and a higher yield.

일본 특허공보 제5819494호Japanese Patent Publication No. 5819494 일본 특허공보 제3140818호Japanese Patent Publication No. 3140818

Organic Synthesis, Coll, Vol. 1, 127 (1941) Organic Synthesis, Coll, Vol. 1, 127 (1941) Organic Synthesis, Coll, Vol. 2, 480 (1943) Organic Synthesis, Coll, Vol. 2, 480 (1943) Synthesis, 49(16), 3692-3699 ; 2017 Synthesis, 49(16), 3692-3699; 2017 Journal of Organic Chemistry, 75(9), 3109-3112 ; 2010 Journal of Organic Chemistry, 75(9), 3109-3112; 2010

본 발명은, 보노프라잔푸마르산염의 제조에 있어서의 합성 중간체 피롤-3-카르복시알데히드 유도체의 제조법 및 당해 유도체를 사용한 신규 보노프라잔푸마르산염의 공업적 제조법을 제공하는 것을 목적으로 한다.An object of the present invention is to provide a process for producing a synthetic intermediate pyrrole-3-carboxyaldehyde derivative in the production of vonoprazan fumarate and a novel industrial process for producing vonoprazan fumarate using the derivative.

본 발명자들은 예의 검토를 실시한 결과, 입수 용이한 플루오로요오드벤젠과 피롤에 의한 커플링 반응, 및 피롤 고리 상 질소 원자의 적절한 보호에 의한 위치 선택적인 포르밀화 반응을 사용함으로써 피롤-3-카르복시알데히드 유도체를 고수율로 또한 간편하게 제조하는 방법을 알아내어, 본 발명을 완성하기에 이르렀다.As a result of intensive examination, the present inventors have found that pyrrole-3-carboxyaldehyde can be obtained by using a coupling reaction with readily available fluoroiodobenzene and pyrrole, and a regioselective formylation reaction by appropriately protecting the nitrogen atom on the pyrrole ring. A method for producing a derivative easily and in high yield was discovered, and the present invention was completed.

in other words

[1] 본 발명은, 하기 일반식 (I),[1] The present invention, the following general formula (I),

[화학식 3][Formula 3]

Figure 112022093424482-pat00003
Figure 112022093424482-pat00003

로 나타내는 피롤 유도체에 있어서, 피롤 고리의 질소 원자에 보호기를 도입하고,In the pyrrole derivative represented by , a protecting group is introduced to the nitrogen atom of the pyrrole ring,

하기 식 (II) :Formula (II):

[화학식 4][Formula 4]

Figure 112022093424482-pat00004
Figure 112022093424482-pat00004

(식 중, P 는 보호기를 나타낸다) 로 나타내는 N 보호 피롤 유도체를 얻고, 추가로 포르밀화에 의해 하기 식 (III)(wherein P represents a protecting group) to obtain an N-protected pyrrole derivative represented by, and further formylating to obtain the following formula (III)

[화학식 3][Formula 3]

Figure 112022093424482-pat00005
Figure 112022093424482-pat00005

으로 나타내는 피롤-3-카르복시알데히드 유도체를 얻고, 추가로 탈보호 반응에 의해 하기 식 (IV)Obtaining a pyrrole-3-carboxyaldehyde derivative represented by, and further deprotection reaction to obtain the following formula (IV)

[화학식 4][Formula 4]

Figure 112022093424482-pat00006
Figure 112022093424482-pat00006

로 나타내는 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조 방법에 관한 것이다.It relates to a method for producing 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde represented by

[2] 또 본 발명은, 상기 P 로 나타내는 보호기가, 실릴계 보호기인 상기 [1] 에 기재된 제조 방법에 관한 것이다.[2] The present invention also relates to the production method described in [1] above, wherein the protecting group represented by P is a silyl-based protecting group.

[3] 또 본 발명은, 상기 P 로 나타내는 보호기가, 트리이소프로필실릴기인 상기 [1] 또는 [2] 에 기재된 제조 방법에 관한 것이다.[3] The present invention also relates to the production method according to [1] or [2] above, wherein the protecting group represented by P is a triisopropylsilyl group.

[4] 또 본 발명은, 상기 일반식 (I) 의 피롤 유도체가,[4] Another aspect of the present invention is that the pyrrole derivative of the general formula (I)

하기 식 (V) :Formula (V):

[화학식 5][Formula 5]

Figure 112022093424482-pat00007
Figure 112022093424482-pat00007

(식 중, L 은 탈리기를 나타낸다) 로 나타내는 오르토플루오로벤젠 유도체를, 금속 촉매 존재하, 피롤과 반응시킴으로써 얻어진 것인 상기 [1] ∼ [3] 에 기재된 화합물 (I) 의 제조 방법에 관한 것이다.(Wherein, L represents a leaving group) Obtained by reacting an orthofluorobenzene derivative represented by pyrrole in the presence of a metal catalyst, the method for producing the compound (I) described in [1] to [3] above will be.

[5] 또 본 발명은, 상기 금속 촉매가 팔라듐 촉매인 상기 [4] 에 기재된 제조 방법에 관한 것이다.[5] The present invention also relates to the production method described in [4] above, wherein the metal catalyst is a palladium catalyst.

[6] 또 본 발명은, 상기 제조 방법에 의해 얻어진 일반식 (IV) 로 나타내는 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드를, 무기 염기 또는 유기 염기의 존재하, 피리딘-3-술포닐클로라이드 또는 그 염과 반응시키고,[6] In addition, the present invention relates to the preparation of 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde represented by the general formula (IV) obtained by the above production method in the presence of an inorganic base or an organic base, reacting with pyridine-3-sulfonyl chloride or a salt thereof;

하기 식 (VI) :Formula (VI):

[화학식 6][Formula 6]

Figure 112022093424482-pat00008
Figure 112022093424482-pat00008

으로 나타내는 피롤 유도체를 얻고, 추가로 메틸아민과 축합시킨 후, 환원 반응에 의해, 하기 식 (VII) :After obtaining a pyrrole derivative represented by and further condensing with methylamine, by a reduction reaction, the following formula (VII):

[화학식 7][Formula 7]

Figure 112022093424482-pat00009
Figure 112022093424482-pat00009

로 나타내는 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민의 제조 방법에 관한 것이다.It relates to a method for producing 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine represented by

[7] 또 본 발명은, 상기 제조 방법에 의해 얻어진 일반식 (VII) 의 화합물과 푸마르산에 의한 1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민모노푸마르산염의 제조 방법에 관한 것이다.[7] Also, the present invention relates to 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H obtained by the compound of formula (VII) obtained by the above production method and fumaric acid. It relates to a method for producing -pyrrol-3-yl] -N-methylmethanamine monofumarate.

본 발명은, 피롤이나 2-플루오로요오드벤젠 등의 입수 용이한 원료를 사용하고, 저가이고 단시간 또한 짧은 공정이고 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드를 양호한 수율 (70 % 이상) 로 얻는 것이 가능하고, 종래법보다 경제성 및 생산성이 높아 공업적 생산에 적합하다. 또한 천이 금속 촉매의 사용에 관해서도 극소량으로 억제하고, 또한 상류 공정에서 사용함으로써, 보다 최종물에 대한 금속 불순물 잔류에 대한 우려를 저감하는 것이 가능하다.The present invention uses readily available raw materials such as pyrrole and 2-fluoroiodobenzene, and produces 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde in good yield by a low-cost, short-time and short process. (70% or more), and is suitable for industrial production because of its economical efficiency and higher productivity than conventional methods. Further, by suppressing the use of the transition metal catalyst to a very small amount and using it in an upstream process, it is possible to further reduce concerns about residual metal impurities in the final product.

이하, 본 발명에 대해 더욱 상세하게 설명한다.Hereinafter, the present invention will be described in more detail.

상기 일반식 (V) 중, L 로 나타내는 탈리기로는, 염소, 브롬, 요오드의 할로겐 원자, 메탄술포닐옥시기나 트리플루오로메탄술포닐옥시기와 같은 저급 알칸술포닐옥시기, 벤젠술포닐옥시기나 p-톨루엔술포닐옥시기와 같은 아릴술포닐옥시기 등을 들 수 있다.In the above general formula (V), as the leaving group represented by L, a halogen atom of chlorine, bromine, or iodine, a lower alkanesulfonyloxy group such as a methanesulfonyloxy group or trifluoromethanesulfonyloxy group, a benzenesulfonyloxy group, or p - arylsulfonyloxy groups such as toluenesulfonyloxy groups; and the like.

상기 일반식 (II) 및 (III) 중, P 로 나타내는 피롤 고리 질소 보호기로는, 실릴계 보호기 혹은 알킬계 보호기, 헤테로아릴계 보호기, 아실계 보호기, 카르바메이트계 보호기 등을 들 수 있고, 실릴계 보호기로는 트리메틸실릴기, 트리에틸실릴기, tert-부틸디메틸실릴기, 트리이소프로필실릴기, tert-부틸디페닐실릴기 등을 들 수 있고, 바람직하게는 tert-부틸디메틸실릴기, 트리이소프로필실릴기 등을 들 수 있다.In the general formulas (II) and (III), the pyrrole ring nitrogen protecting group represented by P includes a silyl protecting group, an alkyl protecting group, a heteroaryl protecting group, an acyl protecting group, a carbamate protecting group, and the like, Examples of the silyl protecting group include a trimethylsilyl group, a triethylsilyl group, a tert-butyldimethylsilyl group, a triisopropylsilyl group, and a tert-butyldiphenylsilyl group, preferably a tert-butyldimethylsilyl group, A triisopropylsilyl group etc. are mentioned.

알킬계 보호기로는 알릴기, 디메톡시메틸기, 디에톡시메틸기, tert-부틸기, 트리페닐메틸기, 벤질기, 4-메톡시벤질기 등을 들 수 있다.Examples of the alkyl-based protecting group include an allyl group, a dimethoxymethyl group, a diethoxymethyl group, a tert-butyl group, a triphenylmethyl group, a benzyl group, and a 4-methoxybenzyl group.

헤테로아릴계 보호기로는 2-피리딜기, 4-피리딜기, 2-피라질기, 2-피리미딜기, 2-트리아질기를 들 수 있다.Examples of the heteroaryl protecting group include a 2-pyridyl group, a 4-pyridyl group, a 2-pyrazyl group, a 2-pyrimidyl group and a 2-triazyl group.

카르바메이트계 보호기로는 메톡시카르보닐기, 에톡시카르보닐기, tert-부톡시카르보닐기, tert-아밀옥시카르보닐기, 2,2,2-트리클로로에톡시카르보닐기, 벤질옥시카르보닐기, p-클로로벤질옥시카르보닐기, p-메톡시벤질옥시카르보닐기, p-니트로벤질옥시카르보닐기, p-페닐아조벤질옥시카르보닐기, p-메톡시페닐아조벤질옥시카르보닐기, 3,5-디메톡시벤질옥시카르보닐기, 3,4,5-트리메톡시벤질옥시카르보닐기, p-비페닐이소프로필옥시카르보닐기, 디이소프로필메틸옥시카르보닐기, 2-(트리메틸실릴)에톡시카르보닐기, 9-플루오레닐메틸옥시카르보닐기 등을 들 수 있다.Examples of the carbamate protecting group include a methoxycarbonyl group, an ethoxycarbonyl group, a tert-butoxycarbonyl group, a tert-amyloxycarbonyl group, a 2,2,2-trichloroethoxycarbonyl group, a benzyloxycarbonyl group, a p-chlorobenzyloxycarbonyl group, p-methoxybenzyloxycarbonyl group, p-nitrobenzyloxycarbonyl group, p-phenylazobenzyloxycarbonyl group, p-methoxyphenylazobenzyloxycarbonyl group, 3,5-dimethoxybenzyloxycarbonyl group, 3,4,5-tri A methoxybenzyloxycarbonyl group, p-biphenyl isopropyloxycarbonyl group, diisopropylmethyloxycarbonyl group, 2-(trimethylsilyl)ethoxycarbonyl group, 9-fluorenylmethyloxycarbonyl group, etc. are mentioned.

또, 그 밖의 보호기로서 메탄술포닐기 등의 알킬술포닐기, p-톨루엔술포닐기 등의 아릴술포닐기, 아세틸기 등의 알킬아실기, 벤조일기 등의 아릴아실기를 사용할 수 있다.In addition, as another protecting group, an alkylsulfonyl group such as methanesulfonyl group, an arylsulfonyl group such as p-toluenesulfonyl group, an alkylacyl group such as acetyl group, and an arylacyl group such as benzoyl group can be used.

이들 보호기 중, 보호기로는 수율 등의 점에서 실릴계 보호기가 바람직하고, 특히 바람직하게는 트리메틸실릴기, 트리에틸실릴기, tert-부틸디메틸실릴기, 트리이소프로필실릴기를 들 수 있고, 더욱 바람직하게는 트리이소프로필실릴기이다.Among these protecting groups, the protecting group is preferably a silyl protecting group from the viewpoint of yield and the like, particularly preferably a trimethylsilyl group, a triethylsilyl group, a tert-butyldimethylsilyl group, and a triisopropylsilyl group, and more preferably More specifically, it is a triisopropylsilyl group.

본 발명에 있어서, 화합물 (V) 로부터 화합물 (I) 을 얻는 반응에 있어서 사용되는 금속 촉매로는, 니켈 촉매나 팔라듐 촉매 등을 사용할 수 있다.In the present invention, as a metal catalyst used in the reaction for obtaining compound (I) from compound (V), a nickel catalyst, a palladium catalyst, or the like can be used.

본 발명에 사용되는 니켈 촉매로는, 비스(1,5-시클로옥타지에닐)니켈 등의 0 가의 니켈 촉매, 니켈클로라이드, 비스(트리페닐포스핀)니켈클로라이드 등의 2 가의 니켈 촉매 등을 들 수 있고, 필요에 따라 트리페닐포스핀, 2-(디-tert-부틸포스피노)비페닐, Xantphos, 비스[2-(디페닐포스피노)페닐]에테르 (이하, DPEPhos), (±)-2,2'-비스(디페닐포스피노)-1,1'-비나프틸 (이하, (±)-BINAP) 등의 포스핀 배위자, N,N,N',N'-테트라메틸에틸렌디아민 등을 첨가할 수 있다.Examples of the nickel catalyst used in the present invention include a zero-valent nickel catalyst such as bis(1,5-cyclooctazienyl)nickel, a divalent nickel catalyst such as nickel chloride and bis(triphenylphosphine)nickel chloride, and the like. and, if necessary, triphenylphosphine, 2-(di-tert-butylphosphino)biphenyl, Xantphos, bis[2-(diphenylphosphino)phenyl]ether (hereinafter referred to as DPEPhos), (±)- Phosphine ligands such as 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (hereinafter referred to as (±)-BINAP), N,N,N',N'-tetramethylethylenediamine etc. can be added.

본 발명에 사용되는 팔라듐 촉매로는, 팔라듐 탄소, 테트라키스트리페닐포스핀팔라듐 등의 0 가의 팔라듐 촉매 혹은 염화팔라듐, 아세트산팔라듐, (디클로로비스(트리-o-톨릴포스핀))팔라듐 등의 2 가의 팔라듐 촉매를 들 수 있고, 필요에 따라 트리페닐포스핀, 2-(디-tert-부틸포스피노)비페닐, Xantphos, DPEPhos, (±)-BINAP 등의 포스핀 배위자 등을 첨가할 수 있다.As the palladium catalyst used in the present invention, a zero-valent palladium catalyst such as palladium carbon or tetrakistriphenylphosphine palladium, or a 2-valent catalyst such as palladium chloride, palladium acetate, (dichlorobis(tri-o-tolylphosphine))palladium, etc. A valent palladium catalyst can be mentioned, and phosphine ligands such as triphenylphosphine, 2-(di-tert-butylphosphino)biphenyl, Xantphos, DPEPhos, and (±)-BINAP can be added as needed. .

본 발명에 사용되는 염기로는, 트리에틸아민, 디이소프로필에틸아민 등의 3 급 아민, 수소화리튬, 수소화나트륨, 수소칼륨, 나트륨아미드, 리튬디이소프로필아미드 (이하, LDA), 리튬헥사메틸디실라지드 (이하, LiHMDS), 에틸마그네슘, 탄산나트륨, 탄산칼슘 등의 금속 염기 등을 첨가할 수 있다.As the base used in the present invention, tertiary amines such as triethylamine and diisopropylethylamine, lithium hydride, sodium hydride, potassium hydrogen, sodium amide, lithium diisopropylamide (hereinafter referred to as LDA), lithium hexamethyl Metal bases such as disilazide (hereinafter referred to as LiHMDS), ethyl magnesium, sodium carbonate, calcium carbonate, and the like may be added.

본 발명에 있어서의 보노프라잔푸마르산염의 제조에 있어서의 합성 중간체 피롤-3-카르복시알데히드 유도체의 제조법 및 당해 유도체를 사용한 보노프라잔푸마르산염의 제조법을 다음에 나타낸다.The production method of the synthetic intermediate pyrrole-3-carboxyaldehyde derivative in the production of vonoprazan fumarate in the present invention and the production method of vonoprazan fumarate using the derivative are shown below.

[화학식 10][Formula 10]

Figure 112022093424482-pat00010
Figure 112022093424482-pat00010

(화합물 (I) 의 제조)(Preparation of compound (I))

화합물 (I) 은 비특허문헌 3 이나 비특허문헌 4 에 기재된 크로스 커플링 반응 등에 의해 제조할 수 있다. 예를 들어, 네기시 커플링 반응을 사용함으로써 할로겐화되어 있지 않은 무치환의 피롤을 사용할 수 있고, 질소 또는 아르곤 등의 불활성 가스 분위기하 1 ∼ 3 당량의 전술한 염기, 바람직하게는 금속 염기, 보다 바람직하게는 수소화나트륨의 디에틸에테르, 시클로프로필메틸에테르, 테트라하이드로푸란, 4-메틸테트라하이드로피란, 디옥산, 모노글라임, 디글라임 등의 에테르류 ; 벤젠, 톨루엔, 자일렌 등의 방향족 탄화수소류 등의 용매 현탁액에 1 ∼ 3 당량의 피롤/상기 용매의 용액을 -10 ℃ ∼ 실온에서 적하하고 10 분 ∼ 1 시간 교반한 후, 1 ∼ 3 당량의 할로겐화아연 (염화아연, 브롬화아연) 등의 무기 아연, 디피발로일아연 등의 유기 아연 (바람직하게는, 할로겐화아연, 특히 바람직하게는 염화아연) 을 첨가하고 실온에서 10 분 ∼ 1 시간 교반한다. 다음으로, 1 ∼ 3 당량의 화합물 (V), 0.0001 ∼ 1.0 당량 (바람직하게는 0.001 ∼ 0.003 당량) 의 팔라듐 등의 상기 촉매와 0.0001 ∼ 1.0 당량 (바람직하게는 0.001 ∼ 0.003 당량) 의 상기 포스핀 배위자를 첨가하고, 실온 ∼ 150 ℃ (바람직하게는 90 ∼ 130 ℃) 에서 5 분 ∼ 24 시간 반응시킴으로써 화합물 (I) 을 제조할 수 있다.Compound (I) can be produced by the cross-coupling reaction described in Non-Patent Document 3 or Non-Patent Document 4 or the like. For example, a non-halogenated unsubstituted pyrrole can be used by using the Negishi coupling reaction, and in an inert gas atmosphere such as nitrogen or argon, 1 to 3 equivalents of the above-mentioned base, preferably a metal base, more preferably ethers such as diethyl ether of sodium hydride, cyclopropylmethyl ether, tetrahydrofuran, 4-methyltetrahydropyran, dioxane, monoglyme, and diglyme; A solution of 1 to 3 equivalents of pyrrole/the above solvent is added dropwise to a solvent suspension of aromatic hydrocarbons such as benzene, toluene, and xylene at -10°C to room temperature, stirred for 10 minutes to 1 hour, and then 1 to 3 equivalents of Inorganic zinc such as zinc halide (zinc chloride, zinc bromide) or organic zinc such as dipivaloyl zinc (preferably zinc halide, particularly preferably zinc chloride) is added and stirred at room temperature for 10 minutes to 1 hour. Next, 1 to 3 equivalents of Compound (V), 0.0001 to 1.0 equivalents (preferably 0.001 to 0.003 equivalents) of the catalyst such as palladium and 0.0001 to 1.0 equivalents (preferably 0.001 to 0.003 equivalents) of the above phosphine Compound (I) can be produced by adding a ligand and reacting at room temperature to 150°C (preferably 90 to 130°C) for 5 minutes to 24 hours.

(화합물 (II) 의 제조)(Preparation of compound (II))

화합물 (II) 는 화합물 (I) 에 보호기를 도입함으로써 제조할 수 있고, 보호기의 도입은 선택하는 보호기에 따라 제조 방법은 상이한데, 일반 공지된 방법을 채용할 수 있다. 예를 들어 실릴계의 보호기의 도입에 있어서는, 1 ∼ 1.5 당량의 전술한 염기, 바람직하게는 금속 염기, 보다 바람직하게는 수소화나트륨의 디에틸에테르, 시클로프로필메틸에테르, 테트라하이드로푸란, 4-메틸테트라하이드로피란, 디옥산, 모노글라임, 디글라임 등의 에테르류 또는 N,N-디메틸포름아미드 등의 비프로톤성 극성 용매 혹은 이들의 혼합 용매, 바람직하게는 에테르류 등의 용매 현탁액에, 화합물 (I) 을 -10 ℃ ∼ 실온에서 적하한 후, 크라운에테르나 테트라에틸렌디아민, 디메틸이미다졸리디논 등의 금속 킬레이트제, 바람직하게는 디메틸이미다졸리디논을 첨가하고, 이어서 1 ∼ 1.5 당량의 보호기 도입 시약을 적하하고 5 분 ∼ 3 시간 반응시킴으로써, 화합물 (II) 를 제조할 수 있다.Compound (II) can be produced by introducing a protecting group into Compound (I). Although the production method for introducing a protecting group differs depending on the protecting group selected, a generally known method can be employed. For example, in the introduction of a silyl-based protecting group, 1 to 1.5 equivalents of the above-mentioned base, preferably a metal base, more preferably diethyl ether of sodium hydride, cyclopropylmethyl ether, tetrahydrofuran, 4-methyl A compound in a solvent suspension of ethers such as tetrahydropyran, dioxane, monoglyme, and diglyme, or aprotic polar solvents such as N,N-dimethylformamide, or mixed solvents thereof, preferably ethers, etc. After adding (I) dropwise at -10°C to room temperature, a metal chelating agent such as crown ether, tetraethylenediamine, or dimethylimidazolidinone, preferably dimethylimidazolidinone, is added, followed by 1 to 1.5 equivalents of Compound (II) can be produced by adding a protecting group introduction reagent dropwise and reacting for 5 minutes to 3 hours.

또, 카르바메이트계 보호기를 도입하는 경우에는, 카르바메이트계 보호기의 종류에 따라 반응 조건은 상이한데, 예를 들어 화합물 (I) 에 대해 tert-부톡시카르보닐 (Boc 기), tert-아밀옥시카르보닐 (Aoc 기) 혹은 벤질옥시카르보닐 (Z 기), 9-플루오레닐메틸옥시카르보닐 (Fmoc) 기, 2,2,2-트리클로로에톡시카르보닐기, 2-(트리메틸실릴)에톡시카르보닐기 등을 도입하는 경우에는, 디옥산, 디옥산/물, 염화메틸렌, 테트라하이드로푸란 등의 용매 중, 트리에틸아민, 피리딘 등의 유기 염기, 수소화나트륨, 수산화칼륨, 수산화나트륨, 탄산수소칼륨, 탄산수소나트륨 등의 무기 염기의 존재하, 디-tert-부틸디카보네이트 ((Boc)2O) 나 tert-부톡시카르보닐클로라이드, 벤질옥시카르보닐클로라이드, tert-아밀옥시카르보닐클로라이드, 9-플루오레닐메틸옥시카르보닐클로라이드, 클로로포름산 2,2,2-트리클로로에틸, 2-(트리메틸실릴)에톡시메틸클로라이드, tert-부톡시카르보닐아지드, 벤질옥시카르보닐아지드 등의 일반 공지된 Boc 기 등의 도입 시약 1 ∼ 1.5 당량을 0 ℃ ∼ 100 ℃ 에서 5 분 ∼ 10 시간 반응시킴으로써 제조할 수 있다.In the case of introducing a carbamate-based protecting group, the reaction conditions are different depending on the type of carbamate-based protecting group. For example, for compound (I), tert-butoxycarbonyl (Boc group), tert- Amyloxycarbonyl (group Aoc) or benzyloxycarbonyl (group Z), 9-fluorenylmethyloxycarbonyl (Fmoc) group, 2,2,2-trichloroethoxycarbonyl group, 2-(trimethylsilyl) When an ethoxycarbonyl group or the like is introduced, organic bases such as triethylamine and pyridine, sodium hydride, potassium hydroxide, sodium hydroxide, and hydrogen carbonate in solvents such as dioxane, dioxane/water, methylene chloride, and tetrahydrofuran Di-tert-butyl dicarbonate ((Boc) 2 O), tert-butoxycarbonyl chloride, benzyloxycarbonyl chloride, tert-amyloxycarbonyl chloride, in the presence of an inorganic base such as potassium or sodium hydrogen carbonate, 9-fluorenylmethyloxycarbonyl chloride, 2,2,2-trichloroethyl chloroformate, 2-(trimethylsilyl)ethoxymethyl chloride, tert-butoxycarbonyl azide, benzyloxycarbonyl azide, etc. It can be produced by reacting 1 to 1.5 equivalents of a generally known Boc group introduction reagent at 0°C to 100°C for 5 minutes to 10 hours.

(화합물 (III) 의 제조)(Preparation of compound (III))

화합물 (III) 은 일반 공지된 포르밀화 반응, 예를 들어 Vilsmeier 반응이나 Rieche 반응, Daff 반응, Reimer-Tiemann 반응 등에 의해 제조할 수 있고, 예를 들어 Vilsmeier 반응에서는 N,N-디메틸포름아미드 (DMF), N-메틸포름아닐리드 (MFA), N-포르밀모르폴린, N,N-디이소프로필포름아미드 등의 N,N-2 치환 포름아미드와 옥시염화인, 염화옥살릴, 염화티오닐, 트리페닐포스핀-브롬, 헥사클로로트리포스파자트리엔 등의 산 염화물로부터 Vilsmeier 시약 ((클로로메틸렌)디메틸이미늄클로라이드) 을 조제 또는 시판품을 구입하고, 이것과 화합물 (II) 를 용매, 예를 들어 옥시염화인 ; 또는 디클로로메탄, 디클로로에탄, 클로로포름, 사염화탄소, 클로로벤젠 등의 할로겐화탄화수소류 ; 벤젠, 톨루엔, 니트로벤젠 등의 방향족 탄화수소류 ; 테트라하이드로푸란, 테트라메틸하이드로피란, 디옥산 등의 에테르류 또는 아세트산에틸, 아세토니트릴, N,N-디메틸포름아미드 등의 비프로톤성 극성 용매 혹은 이들의 혼합 용매, 바람직하게는 에테르계 용매, 방향족 탄화수소류, 비프로톤성 극성 용매 혹은 이들의 혼합 용매, 보다 바람직하게는 테트라메틸하이드로피란 중, 0 ∼ 100 ℃ (바람직하게는 40 ∼ 80 ℃) 에서 0.5 ∼ 12 시간 교반 후 반응시킴으로써, 화합물 (III) 을 제조할 수 있다.Compound (III) can be prepared by a generally known formylation reaction such as Vilsmeier reaction, Rieche reaction, Daff reaction, Reimer-Tiemann reaction, etc., and for example, N,N-dimethylformamide (DMF ), N-methylformanilide (MFA), N-formylmorpholine, N,N-2 substituted formamides such as N,N-diisopropylformamide and phosphorus oxychloride, oxalyl chloride, thionyl chloride, tri Prepare or purchase a commercially available Vilsmeier reagent ((chloromethylene)dimethyliminium chloride) from an acid chloride such as phenylphosphine-bromine or hexachlorotriphosphazatriene, and mix this and compound (II) in a solvent such as phosphorus oxychloride; or halogenated hydrocarbons such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, and chlorobenzene; Aromatic hydrocarbons, such as benzene, toluene, and nitrobenzene; Ethers such as tetrahydrofuran, tetramethylhydropyran, and dioxane, or aprotic polar solvents such as ethyl acetate, acetonitrile, and N,N-dimethylformamide, or mixed solvents thereof, preferably ether-based solvents and aromatics Compound (III ) can be produced.

(화합물 (IV) 의 제조)(Preparation of compound (IV))

화합물 (IV) 는 화합물 (III) 의 탈보호 반응으로부터 제조할 수 있다. 탈보호 반응은 보호기에 따라 상이한데, 일반 공지된 방법을 사용할 수 있고, 예를 들어 보호기가 실릴계 보호기인 경우에는, 테트라하이드로푸란 등의 용액 중 -10 ℃ ∼ 실온에서 테트라부틸암모늄플루오라이드나 HF 피리딘 착물, HF 트리에틸아민 착물 등의 불소원을 반응시킴으로써 제조할 수 있다. 또, 염산이나 트리플루오로아세트산 등의 산성 조건하, 수산화나트륨 수용액 등의 염기성 조건하에서도 동일하게 실릴계 보호기의 탈보호 반응이 진행되고, 화합물 (IV) 를 제조할 수 있다. 탈보호 시약은 화합물 (III) 에 대해 3 ∼ 10 당량 (바람직하게는 5 당량) 의 수산화나트륨 수용액을 사용할 수 있다.Compound (IV) can be prepared from the deprotection reaction of compound (III). The deprotection reaction differs depending on the protecting group, but a generally known method can be used. For example, when the protecting group is a silyl protecting group, tetrabutylammonium fluoride or tetrabutylammonium fluoride in a solution such as tetrahydrofuran at -10 ℃ to room temperature It can be produced by reacting a fluorine source such as HF pyridine complex and HF triethylamine complex. Further, under acidic conditions such as hydrochloric acid or trifluoroacetic acid or under basic conditions such as sodium hydroxide aqueous solution, the deprotection reaction of the silyl-based protecting group proceeds in the same way, and compound (IV) can be produced. As the deprotection reagent, 3 to 10 equivalents (preferably 5 equivalents) of sodium hydroxide aqueous solution can be used relative to compound (III).

또, 카르바메이트계의 보호기의 경우에는, 카르바메이트계 보호기의 종류에 따라 반응 조건은 상이한데, 일반 공지된 방법에 의해 실시할 수 있고, 예를 들어 수소 분위기하, 팔라듐흑, 팔라듐탄소 등의 존재하, 접촉 환원에 의해, 혹은 아세트산/브롬화수소, 트리플루오로아세트산, 염산/유기 용매 등을 보호기에 맞추어 적절히 선택함으로써 실시할 수 있다.In addition, in the case of a carbamate-based protecting group, the reaction conditions are different depending on the type of carbamate-based protecting group, but it can be carried out by a generally known method, for example, palladium black or palladium carbon in a hydrogen atmosphere. It can be carried out by catalytic reduction in the presence of the like, or by appropriately selecting acetic acid/hydrogen bromide, trifluoroacetic acid, hydrochloric acid/organic solvent or the like according to the protecting group.

또 화합물 (IV) 는 화합물 (II) 로부터 화합물 (III) 을 단리하지 않고 원 포트의 조작으로 제조할 수 있다. 이 경우, 상기 화합물 (II) 로부터 화합물 (III) 의 반응 종료 후, 반응계 중에 상기 탈보호를 위한 시약을 첨가함으로써 실시할 수 있다.In addition, compound (IV) can be produced by a one-pot operation without isolating compound (III) from compound (II). In this case, it can be carried out by adding the reagent for deprotection to the reaction system after completion of the reaction of compound (III) from compound (II).

또 화합물 (IV) 는, 화합물 (I) 로부터 화합물 (II), 화합물 (III) 을 단리하지 않고 원 포트의 조작으로 제조할 수도 있고, 예를 들어 상기 화합물 (III) 의 제조에 있어서의 반응 종료 후, 그 반응계에 상기 화합물 (IV) 의 제조에 있어서의 반응 시약을 첨가하고, 반응 종료 후, 추가로 반응계에 상기 탈보호 반응을 위한 시약을 첨가하고, 동일하게 반응시킴으로써, 화합물 (IV) 를 제조할 수 있다. 어느 제조에 있어서의 시약의 양 (量) 관계는, 상기와 동일한 양을 사용할 수 있다.In addition, compound (IV) can also be produced by a one-pot operation without isolating compound (II) or compound (III) from compound (I). After that, the reaction reagent for producing compound (IV) is added to the reaction system, and after completion of the reaction, the reagent for the deprotection reaction is further added to the reaction system and reacted in the same way to obtain compound (IV). can be manufactured Regarding the amount relationship of the reagent in any production, the same amount as described above can be used.

(화합물 (VI) 의 제조)(Preparation of compound (VI))

1 ∼ 1.5 당량의 수소화나트륨/테트라하이드로푸란의 현탁액에 -10 ℃ ∼ 실온에서 화합물 (IV) 의 테트라하이드로푸란 등의 용액을 적하하여 첨가하고, 0.5 ∼ 1 시간 교반한 후, 추가로 크라운에테르나 테트라메틸에틸렌디아민, 디메틸이미다졸리디논 등의 금속 킬레이트제의 존재하, -10 ℃ ∼ 실온에서 0.5 ∼ 1 시간 교반하고, 계속해서 피리딘-3-술포닐클로라이드를 첨가하고, 0 ℃ 에서 0.5 시간 교반한다. 추가로 피리딘-3-술포닐클로라이드를 첨가하고, -10 ℃ ∼ 실온에서 0.5 ∼ 1 시간 교반함으로써, 화합물 (VI) 을 제조할 수 있다.A solution of compound (IV) in tetrahydrofuran or the like is added dropwise to a suspension of 1 to 1.5 equivalents of sodium hydride/tetrahydrofuran at -10°C to room temperature, stirred for 0.5 to 1 hour, and then crown ether or In the presence of a metal chelating agent such as tetramethylethylenediamine or dimethylimidazolidinone, stirring is performed at -10°C to room temperature for 0.5 to 1 hour, pyridine-3-sulfonyl chloride is subsequently added, and the mixture is stirred at 0°C for 0.5 hour. Stir. Compound (VI) can be produced by further adding pyridine-3-sulfonyl chloride and stirring at -10°C to room temperature for 0.5 to 1 hour.

또 화합물 (VI) 은, 화합물 (IV) 의 디클로로메탄이나 아세토니트릴 등의 용액 중, 0 ℃ ∼ 실온에서 트리에틸아민이나 N,N-디이소프로필아민 등의 염기, 촉매량의 4-디메틸아미노피리딘, 피리딘-3-술포닐클로라이드를 첨가하고 실온 ∼ 100 ℃ 에서 0.5 ∼ 12 시간 교반함으로써 제조할 수 있다.In addition, compound (VI) is obtained from a solution of compound (IV) in dichloromethane or acetonitrile at 0°C to room temperature with a base such as triethylamine or N,N-diisopropylamine, or a catalytic amount of 4-dimethylaminopyridine. , It can manufacture by adding pyridine-3-sulfonyl chloride and stirring at room temperature - 100 degreeC for 0.5 to 12 hours.

(화합물 (VII) 의 제조)(Preparation of compound (VII))

화합물 (VI) 의 메탄올 등의 용액에 0 ℃ ∼ 실온에서 메틸아민의 메탄올 등의 용액을 적하하여 첨가하고, 0.5 ∼ 1 시간 교반하고, 이것을 0 ℃ ∼ 실온에서 수소화붕소나트륨 등의 환원제를 1 ∼ 3 당량 첨가하고, 0.5 ∼ 1 시간 반응시킴으로써, 화합물 (VII) 을 얻을 수 있다.A solution of methylamine in methanol or the like is added dropwise to a solution of compound (VI) in methanol or the like at 0°C to room temperature, stirred for 0.5 to 1 hour, and then added with a reducing agent such as sodium borohydride at 0°C to room temperature. Compound (VII) can be obtained by adding 3 equivalents and reacting for 0.5 to 1 hour.

(보노프라잔푸마르산염의 제조)(Preparation of vonoprazan fumarate)

화합물 (VII) 의 아세트산에틸, 메탄올 등의 용액에 0 ℃ ∼ 실온에서 푸마르산의 메탄올 등의 용액을 첨가하고, 0.5 ∼ 1 시간 교반하고, 석출된 결정을 여과 채취하고, 필요에 따라 메탄올/물로 재결정함으로써, 보노프라잔푸마르산염을 제조할 수 있다.A solution of fumaric acid in methanol or the like is added to a solution of compound (VII) in ethyl acetate or methanol at 0°C to room temperature, stirred for 0.5 to 1 hour, and the precipitated crystals are collected by filtration and, if necessary, recrystallized from methanol/water. By doing so, vonoprazan fumarate can be produced.

실시예Example

이하에 실시예, 비교예 및 시험예에 의해 본 발명을 보다 상세하게 설명하지만, 본 발명은 이들로 한정되는 것은 아니다.The present invention will be described in more detail below with examples, comparative examples and test examples, but the present invention is not limited thereto.

실시예 1Example 1

2-(2-플루오로페닐)-1H-피롤의 제조Preparation of 2-(2-fluorophenyl)-1H-pyrrole

수소화나트륨 (60 % 유동 파라핀에 분산, 1.2 g, 30.0 mmol) 과 테트라하이드로푸란 (10 ㎖) 의 현탁액에 빙랭하 피롤 (2.1 ㎖, 30.0 mmol) 을 적하하고 0.5 시간 교반한 후, 염화아연 (4.1 g, 30.0 mmol) 을 첨가하고 실온에서 0.5 시간 교반하였다. 계속해서 아세트산팔라듐 (11 ㎎, 0.05 mmol), 2-(디-tert-부틸포스피노)비페닐 (15 ㎎, 0.05 mmol) 및 1-플루오로-2-요오드벤젠 (1.1 ㎖, 10.0 mmol) 을 첨가하고 탈기 후, 60 ℃ 에서 6 시간 교반하였다. 반응 혼합물을 0 ℃ 에서 냉각시키면서 물을 적하하고, 불용물을 여과한 후, 아세트산에틸로 분액하였다. 수층에 아세트산에틸을 첨가하고 다시 추출한 후, 유기층을 합하고 포화 식염수로 세정하였다. 감압하 용매를 증류 제거 후, 실리카 겔 칼럼 크로마토그래피로 정제하고 감압하 건조시킴으로써 표제 화합물 (1.18 g, 수율 74 %) 을 얻었다.To a suspension of sodium hydride (dispersed in 60% liquid paraffin, 1.2 g, 30.0 mmol) and tetrahydrofuran (10 mL), pyrrole (2.1 mL, 30.0 mmol) was added dropwise under ice-cooling, stirred for 0.5 hour, and zinc chloride (4.1 g, 30.0 mmol) was added and stirred at room temperature for 0.5 hour. Then palladium acetate (11 mg, 0.05 mmol), 2-(di-tert-butylphosphino)biphenyl (15 mg, 0.05 mmol) and 1-fluoro-2-iodobenzene (1.1 mL, 10.0 mmol) were added. After adding and degassing, it stirred at 60 degreeC for 6 hours. Water was added dropwise while cooling the reaction mixture at 0°C, and after filtering the insoluble matter, the mixture was separated with ethyl acetate. After adding ethyl acetate to the aqueous layer and extracting again, the organic layers were combined and washed with saturated brine. The solvent was distilled off under reduced pressure, purified by silica gel column chromatography, and dried under reduced pressure to obtain the title compound (1.18 g, yield 74%).

Figure 112022093424482-pat00011
Figure 112022093424482-pat00011

실시예 2Example 2

2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤의 제조Preparation of 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole

수소화나트륨 (60 % 유동 파라핀에 분산, 64 ㎎, 1.61 mmol) 과 테트라하이드로푸란 (2 ㎖) 의 현탁액에 빙랭하 2-(2-플루오로페닐)-1H-피롤 (172 ㎎, 1.07 mmol) 의 테트라하이드로푸란 (2 ㎖) 용액을 적하하고 0.5 시간 교반한 후, 15-크라운-5-에테르 (0.32 ㎖, 1.61 mmol) 를 첨가하고 0 ℃ 에서 0.5 시간 교반하였다. 계속해서 트리이소프로필실릴클로라이드 (0.35 ㎖, 1.61 mmol) 를 적하하고 실온에서 4 시간 교반하였다. 0 ℃ 까지 냉각시키고 물을 적하하고 아세트산에틸로 분액하였다. 수층에 아세트산에틸을 첨가하고 다시 추출한 후, 유기층을 합하고 포화 식염수로 세정하였다. 감압하 용매를 증류 제거 후, 실리카 겔 칼럼으로 정제하고 감압하 건조시킴으로써 표제 화합물 (272 ㎎, 수율 80 %) 을 얻었다.In a suspension of sodium hydride (60% dispersed in liquid paraffin, 64 mg, 1.61 mmol) and tetrahydrofuran (2 mL), 2-(2-fluorophenyl)-1H-pyrrole (172 mg, 1.07 mmol) was added under ice-cooling. A solution of tetrahydrofuran (2 ml) was added dropwise and stirred for 0.5 hour, then 15-crown-5-ether (0.32 ml, 1.61 mmol) was added and stirred at 0°C for 0.5 hour. Then, triisopropylsilyl chloride (0.35 ml, 1.61 mmol) was added dropwise, and the mixture was stirred at room temperature for 4 hours. After cooling to 0°C, water was added dropwise and partitioned with ethyl acetate. After adding ethyl acetate to the aqueous layer and extracting again, the organic layers were combined and washed with saturated brine. The solvent was distilled off under reduced pressure, purified with a silica gel column, and dried under reduced pressure to obtain the title compound (272 mg, yield 80%).

Figure 112022093424482-pat00012
Figure 112022093424482-pat00012

실시예 3Example 3

5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조Preparation of 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde

2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤 (100 ㎎, 0.32 mmol) 의 디클로로메탄 (3.0 ㎖) 용액에 빙랭하 Vilsmeier 시약 (123 ㎎, 0.96 mmol) 을 첨가하고 40 ℃ 에서 0.5 시간 교반하였다. 용매를 감압하 증류 제거한 후에 수산화나트륨 수용액 (1.0 M, 3 ㎖) 을 첨가하고 실온에서 6 시간 교반하고, 아세트산에틸을 첨가하여 분액하였다. 수층에 아세트산에틸을 첨가하고 다시 추출한 후, 유기층을 합하고 포화 식염수로 세정하였다. 실리카 겔 칼럼으로 정제하고 감압하 건조시킴으로써 표제 화합물 (48 ㎎, 수율 80 %) 을 얻었다.Vilsmeier's reagent (123 mg, 0.96 mmol) was added to a solution of 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole (100 mg, 0.32 mmol) in dichloromethane (3.0 mL) under ice-cooling. It was added and stirred at 40 degreeC for 0.5 hour. After distilling off the solvent under reduced pressure, sodium hydroxide aqueous solution (1.0 M, 3 ml) was added, and the mixture was stirred at room temperature for 6 hours, and then ethyl acetate was added to separate the mixture. After adding ethyl acetate to the aqueous layer and extracting again, the organic layers were combined and washed with saturated brine. Purification with a silica gel column and drying under reduced pressure gave the title compound (48 mg, yield 80%).

Figure 112022093424482-pat00013
Figure 112022093424482-pat00013

실시예 4Example 4

5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조Preparation of 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde

수소화나트륨 (60 % 유동 파라핀에 분산, 1.2 g, 30.0 mmol) 과 4-메틸테트라하이드로피란 (10 ㎖) 의 현탁액에 빙랭하 피롤 (2.1 ㎖, 30.0 mmol) 을 적하하고 0.5 시간 교반한 후, 염화아연 (4.1 g, 30.0 mmol) 을 첨가하고 실온에서 0.5 시간 교반하였다. 계속해서 아세트산팔라듐 (11 ㎎, 0.05 mmol), 2-(디-tert-부틸포스피노)비페닐 (15 ㎎, 0.05 mmol) 및 1-플루오로-2-요오드벤젠 (1.1 ㎖, 10.0 mmol) 을 첨가하고, 100 ℃ 에서 0.5 시간 교반하였다. 반응 혼합물을 0 ℃ 에서 냉각시키면서 28 % 암모니아수를 적하하고, 불용물을 여과한 후, 아세트산에틸로 분액하였다. 감압하 용매를 증류 제거 후, 2-(2-플루오로페닐)-1H-피롤을 미정제 생성물로서 얻었다.Pyrrole (2.1 ml, 30.0 mmol) was added dropwise to a suspension of sodium hydride (dispersed in 60% liquid paraffin, 1.2 g, 30.0 mmol) and 4-methyltetrahydropyran (10 ml) under ice-cooling, stirred for 0.5 hour, and then chlorinated. Zinc (4.1 g, 30.0 mmol) was added and stirred at room temperature for 0.5 hour. Then palladium acetate (11 mg, 0.05 mmol), 2-(di-tert-butylphosphino)biphenyl (15 mg, 0.05 mmol) and 1-fluoro-2-iodobenzene (1.1 mL, 10.0 mmol) were added. It was added and stirred at 100 degreeC for 0.5 hour. 28% aqueous ammonia was added dropwise while cooling the reaction mixture at 0°C, and after filtering the insoluble matter, the mixture was separated with ethyl acetate. After distilling off the solvent under reduced pressure, 2-(2-fluorophenyl)-1H-pyrrole was obtained as a crude product.

수소화나트륨 (60 % 유동 파라핀에 분산, 600 ㎎, 15 mmol) 과 테트라하이드로푸란 (10 ㎖) 및 디메틸이미다졸리디논 (2 ㎖) 의 현탁액에 얻어진 2-(2-플루오로페닐)-1H-피롤의 미정제 생성물의 테트라하이드로푸란 (2 ㎖) 용액을 빙랭하 적하하고 0.5 시간 교반하였다. 계속해서 트리이소프로필실릴클로라이드 (3.2 ㎖, 15 mmol) 를 적하하고 실온에서 2 시간 교반하였다. 0 ℃ 까지 냉각시키면서 물을 적하하고 아세트산에틸로 분액하였다. 감압하 용매를 증류 제거 후, 헵탄과 물로 다시 분액 조작을 실시하고 감압하 용매를 증류 제거함으로써, 2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤을 미정제 생성물로서 얻었다.2-(2-fluorophenyl)-1H- obtained in a suspension of sodium hydride (60% dispersed in liquid paraffin, 600 mg, 15 mmol) in tetrahydrofuran (10 mL) and dimethylimidazolidinone (2 mL) A solution of the crude product of pyrrole in tetrahydrofuran (2 ml) was added dropwise under ice-cooling, followed by stirring for 0.5 hour. Then, triisopropylsilyl chloride (3.2 ml, 15 mmol) was added dropwise, and the mixture was stirred at room temperature for 2 hours. Water was added dropwise while cooling to 0°C, and the mixture was separated with ethyl acetate. After the solvent was distilled off under reduced pressure, 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole was crudely obtained by performing a liquid separation operation again with heptane and water and distilling off the solvent under reduced pressure. obtained as a product.

얻어진 2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤의 미정제 생성물의 디클로로메탄 (50 ㎖) 용액에 빙랭하 Vilsmeier 시약 (3.8 g, 30 mmol) 을 첨가하고 40 ℃ 에서 0.5 시간 교반하였다. 용매를 감압하 증류 제거한 후에 수산화나트륨 수용액 (1.0 M, 100 ㎖) 을 첨가하고 실온에서 6 시간 교반하고, 아세트산에틸을 첨가하여 분액하였다. 유기층을 포화 식염수로 세정 후, 감압하 용매를 증류 제거하였다. 헵탄 및 아세트산에틸로 재결정을 실시하고, 감압하 건조시킴으로써 표제 화합물 (1.34 g, 수율 70 %) 을 얻었다.To a solution of the obtained crude product of 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole in dichloromethane (50 mL) was added Vilsmeier reagent (3.8 g, 30 mmol) under ice-cooling. It stirred at 40 degreeC for 0.5 hour. After distilling off the solvent under reduced pressure, an aqueous solution of sodium hydroxide (1.0 M, 100 ml) was added, and the mixture was stirred at room temperature for 6 hours, and ethyl acetate was added to separate the mixture. After washing the organic layer with saturated brine, the solvent was distilled off under reduced pressure. The title compound (1.34 g, yield 70%) was obtained by recrystallization from heptane and ethyl acetate and drying under reduced pressure.

실시예 5Example 5

5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-카르복시알데히드의 제조Preparation of 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carboxyaldehyde

수소화나트륨 (60 % 유동 파라핀에 분산, 32 ㎎, 0.79 mmol) 과 테트라하이드로푸란 (2 ㎖) 의 현탁액에 빙랭하 5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드 (100 ㎎, 0.53 mmol) 의 테트라하이드로푸란 (2 ㎖) 용액을 적하하고 0.5 시간 교반한 후, 15-크라운-5-에테르 (0.16 ㎖, 0.79 mmol) 를 첨가하고 0 ℃ 에서 0.5 시간 교반하였다. 계속해서 피리딘-3-술포닐클로라이드 (95 ㎕, 0.79 mmol) 를 첨가하고, 0 ℃ 에서 0.5 시간 교반하였다. 추가로 피리딘-3-술포닐클로라이드 (95 ㎕, 0.79 mmol) 를 첨가하고, 0 ℃ 에서 0.5 시간 교반하였다. 물을 적하하고 아세트산에틸로 분액하였다. 수층에 아세트산에틸을 첨가하고 다시 추출한 후, 유기층을 합하고 포화 식염수로 세정하였다. 감압하 용매를 증류 제거 후, 실리카 겔 칼럼으로 정제하고 감압하 건조시킴으로써 표제 화합물 (167 ㎎, 수율 95 %) 을 얻었다.A suspension of sodium hydride (60% dispersed in liquid paraffin, 32 mg, 0.79 mmol) and tetrahydrofuran (2 mL) was added with 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde (100 mg) under ice-cooling. , 0.53 mmol) in tetrahydrofuran (2 ml) was added dropwise and stirred for 0.5 hour, then 15-crown-5-ether (0.16 ml, 0.79 mmol) was added and stirred at 0°C for 0.5 hour. Subsequently, pyridine-3-sulfonyl chloride (95 µL, 0.79 mmol) was added, and the mixture was stirred at 0°C for 0.5 hour. Further, pyridine-3-sulfonyl chloride (95 µl, 0.79 mmol) was added, and the mixture was stirred at 0°C for 0.5 hour. Water was added dropwise, and the mixture was separated with ethyl acetate. After adding ethyl acetate to the aqueous layer and extracting again, the organic layers were combined and washed with saturated brine. The solvent was distilled off under reduced pressure, purified with a silica gel column, and dried under reduced pressure to obtain the title compound (167 mg, yield 95%).

Figure 112022093424482-pat00014
Figure 112022093424482-pat00014

실시예 6Example 6

1-[5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-일]-N-메틸메탄아민푸마르산염의 제조Preparation of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate

5-(2-플루오로페닐)-1-(피리딘-3-일술포닐)-1H-피롤-3-카르복시알데히드 (100 ㎎, 0.30 mmol) 의 메탄올 (3 ㎖) 용액에 실온에서 메틸아민의 메탄올 용액 (2.0 M, 1.06 ㎖, 2.12 mmol) 을 적하하고, 0.5 시간 교반하였다. 0 ℃ 로 냉각시키고, 수소화붕소나트륨 (34 ㎎, 0.91 mmol) 을 첨가하고 0.5 시간 교반하였다. 0 ℃ 에서 1 규정 염산 (3 ㎖) 을 적하하고, 실온에서 0.5 시간 교반하였다. 포화 중조수, 아세트산에틸을 첨가하고 분액하였다. 수층에 아세트산에틸을 첨가하고 다시 추출한 후, 유기층을 합하고 포화 식염수로 세정하였다. 유기층을 농축한 후, 아세트산에틸 (3 ㎖) 을 첨가하고, 푸마르산 (39 ㎎, 0.30 mmol) 의 메탄올 (0.3 ㎖) 용액을 첨가하였다. 실온에서 30 분간 교반 후, 석출된 결정을 여과하고, 아세트산에틸과 메탄올로 세정하고, 미정제 생성물을 얻었다. 얻어진 미정제 결정을 메탄올 및 물로부터 재결정하고, 석출된 결정을 여과 채취 후 감압하 건조시킴으로써 표제 화합물 (90 ㎎, 수율 64 %) 을 얻었다.To a solution of 5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrole-3-carboxyaldehyde (100 mg, 0.30 mmol) in methanol (3 mL) at room temperature, add methylamine to methanol A solution (2.0 M, 1.06 ml, 2.12 mmol) was added dropwise and stirred for 0.5 hour. After cooling to 0°C, sodium borohydride (34 mg, 0.91 mmol) was added and the mixture was stirred for 0.5 hour. 1 normal hydrochloric acid (3 ml) was added dropwise at 0°C, and the mixture was stirred at room temperature for 0.5 hour. Saturated sodium bicarbonate water and ethyl acetate were added and separated. After adding ethyl acetate to the aqueous layer and extracting again, the organic layers were combined and washed with saturated brine. After concentrating the organic layer, ethyl acetate (3 mL) was added, followed by a solution of fumaric acid (39 mg, 0.30 mmol) in methanol (0.3 mL). After stirring at room temperature for 30 minutes, the precipitated crystals were filtered and washed with ethyl acetate and methanol to obtain a crude product. The obtained crude crystals were recrystallized from methanol and water, and the precipitated crystals were collected by filtration and dried under reduced pressure to obtain the title compound (90 mg, yield 64%).

Figure 112022093424482-pat00015
Figure 112022093424482-pat00015

실시예 7Example 7

5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조Preparation of 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde

수소화나트륨 (60 % 유동 파라핀에 분산, 8.8 g, 220.0 mmol) 과 4-메틸테트라하이드로피란 (100 ㎖) 의 현탁액에 빙랭하 피롤 (15.7 ㎖, 220.0 mmol) 을 적하하고 0.5 시간 교반한 후, 염화아연 (30.3 g, 220.0 mmol) 을 첨가하고 실온에서 0.5 시간 교반하였다. 계속해서 아세트산팔라듐 (56.1 ㎎, 0.25 mmol), 2-(디-tert-부틸포스피노)비페닐 (74.6 ㎎, 0.25 mmol) 및 1-플루오로-2-요오드벤젠 (11.5 ㎖, 100.0 mmol) 을 첨가하고, 약 100 ℃ 에서 1 시간 교반하였다. 빙랭하, 반응 혼합물에 수산화나트륨 수용액 (5.0 N, 220.0 mmol) 을 적하하고, 실온에서 0.5 시간 교반하였다. 불용물을 여과, 톨루엔 (100 ㎖) 을 사용하여 세정한 후, 유기층을 분리하여 수층을 톨루엔 (100 ㎖) 을 사용하여 추출하였다. 유기층을 합하고 증류수 (167 ㎖) 및 포화 식염수 (167 ㎖) 로 세정하였다. 감압하 용매를 증류 제거 후, 잔류물에 톨루엔 (167 ㎖) 을 첨가하였다. 감압하 용매를 증류 제거함으로써, 2-(2-플루오로페닐)-1H-피롤을 미정제 생성물 (20.9 g) 로서 얻었다.Pyrrole (15.7 mL, 220.0 mmol) was added dropwise to a suspension of sodium hydride (dispersed in 60% liquid paraffin, 8.8 g, 220.0 mmol) and 4-methyltetrahydropyran (100 mL) under ice-cooling, stirred for 0.5 hour, and then chlorinated. Zinc (30.3 g, 220.0 mmol) was added and stirred at room temperature for 0.5 hour. Then palladium acetate (56.1 mg, 0.25 mmol), 2-(di-tert-butylphosphino)biphenyl (74.6 mg, 0.25 mmol) and 1-fluoro-2-iodobenzene (11.5 mL, 100.0 mmol) were added. It was added and stirred at about 100 degreeC for 1 hour. Sodium hydroxide aqueous solution (5.0 N, 220.0 mmol) was added dropwise to the reaction mixture under ice-cooling, and the mixture was stirred at room temperature for 0.5 hour. After filtration of the insoluble matter and washing with toluene (100 ml), the organic layer was separated and the aqueous layer was extracted with toluene (100 ml). The organic layers were combined and washed with distilled water (167 mL) and saturated brine (167 mL). After distilling off the solvent under reduced pressure, toluene (167 ml) was added to the residue. By distilling off the solvent under reduced pressure, 2-(2-fluorophenyl)-1H-pyrrole was obtained as a crude product (20.9 g).

수소화나트륨 (60 % 유동 파라핀에 분산, 4.4 g, 110.0 mmol) 과 테트라하이드로푸란 (100 ㎖) 및 디메틸이미다졸리디논 (32.6 ㎖, 300.0 mmol) 의 현탁액에 얻어진 2-(2-플루오로페닐)-1H-피롤의 미정제 생성물의 테트라하이드로푸란 (10 ㎖) 용액을 빙랭하 적하하고, 테트라하이드로푸란 (10 ㎖) 으로 씻고, 0.5 시간 교반하였다. 계속해서 트리이소프로필실릴클로라이드 (23.5 ㎖, 110.0 mmol) 를 적하하고 실온에서 1 시간 교반하였다. 빙욕하, 증류수 (17 ㎖) 를 적하하고, 추가로 증류수 (167 ㎖) 를 첨가하였다. 아세트산에틸 (84 ㎖) 을 사용하여 2 회 추출을 실시하고, 증류수 (167 ㎖) 및 포화 식염수 (167 ㎖) 로 세정하였다. 감압하 용매를 증류 제거 후, 잔류물에 톨루엔 (167 ㎖) 을 첨가하였다. 감압하 용매를 증류 제거 후, 감압하 용매를 증류 제거함으로써, 2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤을 미정제 생성물 (45.2 g) 로서 얻었다.2-(2-fluorophenyl) obtained in a suspension of sodium hydride (60% dispersed in liquid paraffin, 4.4 g, 110.0 mmol) in tetrahydrofuran (100 mL) and dimethylimidazolidinone (32.6 mL, 300.0 mmol) A solution of the crude product of -1H-pyrrole in tetrahydrofuran (10 ml) was added dropwise under ice-cooling, washed with tetrahydrofuran (10 ml), and stirred for 0.5 hour. Then, triisopropylsilyl chloride (23.5 ml, 110.0 mmol) was added dropwise, and the mixture was stirred at room temperature for 1 hour. Distilled water (17 ml) was added dropwise under an ice bath, and further distilled water (167 ml) was added. Extraction was performed twice using ethyl acetate (84 ml), and washed with distilled water (167 ml) and saturated brine (167 ml). After distilling off the solvent under reduced pressure, toluene (167 ml) was added to the residue. After distilling off the solvent under reduced pressure, the solvent was distilled off under reduced pressure to obtain 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole as a crude product (45.2 g).

디클로로메탄 (100 ㎖) 에 염화옥살릴 (17.2 ㎖, 200.0 mmol) 을 첨가하고, DMF (15.5 ㎖, 200.0 mmol) 를 빙랭하 적하하고, 0.5 시간 교반하였다. 얻어진 2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤의 미정제 생성물의 4-메틸테트라하이드로피란 (100 ㎖) 용액을 한번에 첨가하고 약 50 ℃ 에서 3 시간 교반하였다. 빙랭하, 수산화나트륨 수용액 (5.0 M, 100 ㎖) 을 첨가하고 실온에서 밤새 교반하였다. 유기층을 분리하고, 수층을 아세트산에틸 (200 ㎖) 로 분액하였다. 유기층을 합하고, 포화 식염수 (200 ㎖) 로 세정 후, 감압하 용매를 증류 제거하였다. 얻어진 고체 잔류물에 아세트산에틸 (47 ㎖) 을 첨가하고, 약 70 ℃ 에서 용해 후, 헵탄 (300 ㎖) 을 첨가하였다. 실온하 방랭 후, 빙욕하에서 1 시간 교반하고, 석출된 결정을 여과 채취, 냉각시킨 아세트산에틸 : 헵탄 (1 : 6, 70 ㎖) 으로 세정하였다. 감압하에서 50 ℃, 1.5 시간 건조시킴으로써 표제 화합물 (13.6 g, 수율 72 %) 을 얻었다.Oxalyl chloride (17.2 ml, 200.0 mmol) was added to dichloromethane (100 ml), DMF (15.5 ml, 200.0 mmol) was added dropwise under ice-cooling, and the mixture was stirred for 0.5 hour. A 4-methyltetrahydropyran (100 ml) solution of the obtained crude product of 2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole was added at once and stirred at about 50°C for 3 hours. did Under ice-cooling, aqueous sodium hydroxide solution (5.0 M, 100 ml) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated, and the aqueous layer was partitioned with ethyl acetate (200 ml). The organic layers were combined, washed with saturated brine (200 ml), and the solvent was distilled off under reduced pressure. Ethyl acetate (47 ml) was added to the obtained solid residue, and after dissolving at about 70°C, heptane (300 ml) was added. After cooling at room temperature, the mixture was stirred in an ice bath for 1 hour, and the precipitated crystals were collected by filtration and washed with cooled ethyl acetate:heptane (1:6, 70 ml). The title compound (13.6 g, yield 72%) was obtained by drying under reduced pressure at 50°C for 1.5 hours.

실시예 8Example 8

5-(2-플루오로페닐)-1H-피롤-3-카르복시알데히드의 제조 (2-(2-플루오로페닐)-1H-피롤로부터의 원 포트 합성)Preparation of 5-(2-fluorophenyl)-1H-pyrrole-3-carboxyaldehyde (one pot synthesis from 2-(2-fluorophenyl)-1H-pyrrole)

2-(2-플루오로페닐)-1H-피롤 (10.0 g, 62.0 mmol) 의 4-메틸테트라하이드로피란 (62 ㎖) 용액에 디메틸이미다졸리디논 (20.0 ㎖, 186 mmol) 을 첨가한 후, 수소화나트륨 (60 % 유동 파라핀에 분산, 2.7 g, 68.2 mmol) 을 빙랭하 천천히 첨가하고 10 분간 교반하였다. 계속해서 트리이소프로필실릴클로라이드 (14.6 ㎖, 68.2 mmol) 를 적하하고 빙랭하 2 시간 교반하였다. 염화옥살릴 (10.6 ㎖, 124 mmol) 과 DMF (9.65 ㎖, 124 mmol) 로부터 조제한 Vilsmeier 시약의 디클로로메탄 (90 ㎖) 용액에, 2-(2-플루오로페닐)-1H-피롤의 반응 용액을 빙랭하 한번에 첨가하고, 4-메틸테트라하이드로피란 (20 ㎖) 으로 씻고, 약 60 ℃ 에서 2 시간 교반하였다. 빙랭하, 수산화나트륨 수용액 (2.0 M, 310 ㎖) 을 첨가하고 실온에서 밤새 교반하였다. 유기층을 분리하고, 수층을 아세트산에틸 (120 ㎖) 로 분액하였다. 유기층을 합하고, 포화 식염수 (120 ㎖) 로 세정 후, 감압하 용매를 증류 제거하였다. 얻어진 고체 잔류물에 아세트산에틸 (29 ㎖) 을 첨가하고, 약 70 ℃ 에서 용해 후, 헵탄 (180 ㎖) 을 첨가하였다. 실온하 방랭 후, 빙욕하에서 1 시간 교반하고, 석출된 결정을 여과 채취, 냉각시킨 아세트산에틸 : 헵탄 (1 : 6, 42 ㎖) 으로 세정하였다. 감압하에서 50 ℃, 1.5 시간 건조시킴으로써 표제 화합물 (8.30 g, 수율 71 %) 을 얻었다.After adding dimethylimidazolidinone (20.0 mL, 186 mmol) to a solution of 2-(2-fluorophenyl)-1H-pyrrole (10.0 g, 62.0 mmol) in 4-methyltetrahydropyran (62 mL), Sodium hydride (dispersed in 60% liquid paraffin, 2.7 g, 68.2 mmol) was slowly added under ice-cooling, followed by stirring for 10 minutes. Then, triisopropylsilyl chloride (14.6 ml, 68.2 mmol) was added dropwise, and the mixture was stirred for 2 hours under ice-cooling. A reaction solution of 2-(2-fluorophenyl)-1H-pyrrole in dichloromethane (90 mL) solution of Vilsmeier's reagent prepared from oxalyl chloride (10.6 mL, 124 mmol) and DMF (9.65 mL, 124 mmol) was added to ice. It was added at once under cooling, washed with 4-methyltetrahydropyran (20 ml), and stirred at about 60°C for 2 hours. Under ice-cooling, aqueous sodium hydroxide solution (2.0 M, 310 ml) was added, and the mixture was stirred at room temperature overnight. The organic layer was separated, and the aqueous layer was partitioned with ethyl acetate (120 mL). The organic layers were combined, washed with saturated brine (120 ml), and the solvent was distilled off under reduced pressure. Ethyl acetate (29 ml) was added to the obtained solid residue, and after dissolving at about 70°C, heptane (180 ml) was added. After cooling at room temperature, the mixture was stirred in an ice bath for 1 hour, and the precipitated crystals were collected by filtration and washed with cooled ethyl acetate:heptane (1:6, 42 ml). The title compound (8.30 g, yield 71%) was obtained by drying under reduced pressure at 50°C for 1.5 hours.

Claims (1)

2-(2-플루오로페닐)-1-(트리이소프로필실릴)-1H-피롤.2-(2-fluorophenyl)-1-(triisopropylsilyl)-1H-pyrrole.
KR1020227030825A 2017-12-27 2018-12-26 Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate KR102500124B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017251749 2017-12-27
JPJP-P-2017-251749 2017-12-27
PCT/JP2018/047697 WO2019131695A1 (en) 2017-12-27 2018-12-26 Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate
KR1020207019383A KR102443292B1 (en) 2017-12-27 2018-12-26 Preparation of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207019383A Division KR102443292B1 (en) 2017-12-27 2018-12-26 Preparation of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate

Publications (2)

Publication Number Publication Date
KR20220127369A KR20220127369A (en) 2022-09-19
KR102500124B1 true KR102500124B1 (en) 2023-02-14

Family

ID=67063705

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207019383A KR102443292B1 (en) 2017-12-27 2018-12-26 Preparation of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate
KR1020227030825A KR102500124B1 (en) 2017-12-27 2018-12-26 Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020207019383A KR102443292B1 (en) 2017-12-27 2018-12-26 Preparation of 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate

Country Status (3)

Country Link
JP (1) JP7227925B2 (en)
KR (2) KR102443292B1 (en)
WO (1) WO2019131695A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113549054B (en) * 2020-04-23 2024-03-15 鲁南制药集团股份有限公司 Vonoprazan fumarate intermediate and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106187852A (en) 2016-07-07 2016-12-07 江西同和药业股份有限公司 A kind of preparation method of Vonoprazan fumarate intermediate

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5819494B2 (en) 1978-11-06 1983-04-18 トヨタ自動車株式会社 Passive seat belt device
IL87222A (en) * 1987-07-29 1993-04-04 American Cyanamid Co Arylpyrroles, methods for thepreparation thereof andinsecticidal, acaricidal andnematicidal compositionscontaining them
US5101042A (en) 1990-12-11 1992-03-31 American Cyanamid Company Process for the preparation of insecticidal, nematicidal and acaricidal 2-halo-3-substituted-5-arylpyrrole compounds
JP4035559B1 (en) 2005-08-30 2008-01-23 武田薬品工業株式会社 1-Heterocyclylsulfonyl, 2-aminomethyl, 5- (hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
EP3613734B1 (en) 2009-02-25 2021-08-25 Takeda Pharmaceutical Company Limited Process for producing pyrrole compound
CN105440019A (en) * 2015-12-17 2016-03-30 昆明贵研药业有限公司 Preparation method of drug for treating gastric acid related diseases
CN106146466A (en) * 2016-06-30 2016-11-23 珠海赛隆药业股份有限公司(长沙)医药研发中心 Vonoprazan fumarate intermediate, its preparation method and the method for preparation Vonoprazan fumarate
CN106366071B (en) * 2016-08-22 2019-05-07 山东金城医药集团股份有限公司 The preparation method of Vonoprazan fumarate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106187852A (en) 2016-07-07 2016-12-07 江西同和药业股份有限公司 A kind of preparation method of Vonoprazan fumarate intermediate

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
논문 Journal of Medicinal Chemistry, Vol. 55, pp. 4446-4456 (2012.04.18.)
논문 Journal of Organic Chemistry, Vol. 75, No. 9, pp. 3109-3112 (2010.04.12.)
논문 Journal of the American Chemical Society, Vol. 139, No. 32, pp. 10956-10959 (2017.07.27.)

Also Published As

Publication number Publication date
WO2019131695A1 (en) 2019-07-04
CN111527067A (en) 2020-08-11
KR20220127369A (en) 2022-09-19
JP7227925B2 (en) 2023-02-22
KR20200096598A (en) 2020-08-12
KR102443292B1 (en) 2022-09-14
JPWO2019131695A1 (en) 2021-01-14

Similar Documents

Publication Publication Date Title
KR100917698B1 (en) Improved process for the preparation of letrozole
JP3173602B2 (en) Novel intermediate for the production of enyne derivatives and its production method
KR102500124B1 (en) Production method for 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine monofumarate
KR0153523B1 (en) Amidation of pyridines
WO2007135036A1 (en) METHOD OF PREPARING CHIRAL CYCLIC ß-AMINOCARBOXAMIDES
CN108148044B (en) Amide compound and method for preparing Vonoprazan fumarate from same
CN115417816B (en) Preparation method of 3, 6-dibromo-1-chloro-isoquinoline
CN113416162B (en) Double-chiral binaphthyl O-N-N tridentate ligand and preparation method thereof
CN111527067B (en) Process for the preparation of 1- [5- (2-fluorophenyl) -1- (pyridin-3-ylsulfonyl) -1H-pyrrol-3-yl ] -N-methylmethylamine monofumarate
WO2020118597A1 (en) Process for making 1- [ (3r, 4s) -4-cyanotetrahydropyran-3-yl] -3- [ (2-fluoro-6-methoxy-4-pyridyl) amino] pyrazole-4-carboxamide
CN113861167A (en) Preparation method of Voranolan fumarate
WO2021120953A1 (en) Method for synthesizing 1,7-naphthyridine derivative
CN103739541B (en) The preparation method of 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxo-piperidino) phenyl]-2 (1H)-pyridones
CN106957318B (en) Condensed polycyclic indoline compound, preparation method, pharmaceutical composition and application thereof
EP3381900A1 (en) New synthetic path to pharmaceutically acceptable vismodegib
IL168110A (en) Process for production of an acetylenic compound
CN111187197B (en) Synthesis method of Tezacaftor intermediate
CN110683943B (en) Fluoro 1, 3-eneyne compound and preparation method thereof
CN111423405B (en) Method for synthesizing benzopyran 3 alcohol derivative compound
CN108586331B (en) Intermediate for synthesizing nitrogen-containing heterocyclic compound and preparation method thereof
CN107556237B (en) Preparation method of 3- (2-phenethyl) -2-pyridine carboxamide compound
JP5279449B2 (en) Process for producing 5- {4- [2- (5-ethyl-2-pyridyl) ethoxy] benzyl} -2,4-thiazolidinedione hydrochloride
WO2005063678A1 (en) Process for producing phenylacetic acid derivative
KR20220101702A (en) Manufacturing process of chroman compounds
JP2019196359A (en) Chemical process for preparing pyrimidine derivatives and intermediates thereof

Legal Events

Date Code Title Description
E701 Decision to grant or registration of patent right
GRNT Written decision to grant